In summary, the results from HGSOC patients verified the high co-expression of TIM-3 and PD-1 and efficacy of their co-blockades in enhancing the anti-tumor immunity of CD8+TILs and CD11c+ myeloid cells. The gene discussed is HAVCR2; the disease is neoplasm.